1. Home
  2. TGTX vs HLI Comparison

TGTX vs HLI Comparison

Compare TGTX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.16

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Logo Houlihan Lokey Inc.

HLI

Houlihan Lokey Inc.

HOLD

Current Price

$138.52

Market Cap

9.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
HLI
Founded
1993
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
9.6B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
TGTX
HLI
Price
$55.16
$138.52
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$49.80
$194.29
AVG Volume (30 Days)
2.8M
614.6K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
1.54%
EPS Growth
1746.67
6.87
EPS
0.12
6.22
Revenue
$2,785,000.00
$2,617,516,000.00
Revenue This Year
$49.08
$13.77
Revenue Next Year
$26.69
$12.10
P/E Ratio
$457.67
$21.58
Revenue Growth
N/A
9.55
52 Week Low
$25.37
$131.31
52 Week High
$57.38
$211.78

Technical Indicators

Market Signals
Indicator
TGTX
HLI
Relative Strength Index (RSI) 77.96 46.87
Support Level $28.57 $134.84
Resistance Level $57.38 $144.57
Average True Range (ATR) 2.39 3.92
MACD 0.24 0.08
Stochastic Oscillator 81.53 52.69

Price Performance

Historical Comparison
TGTX
HLI

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About HLI Houlihan Lokey Inc.

Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.

Share on Social Networks: